TY - JOUR T1 - A novel G protein-coupled P2 purinoceptor (P2Y3) activated preferentially by nucleoside diphosphates. JF - Molecular Pharmacology JO - Mol Pharmacol SP - 258 LP - 265 VL - 50 IS - 2 AU - T E Webb AU - D Henderson AU - B F King AU - S Wang AU - J Simon AU - A N Bateson AU - G Burnstock AU - E A Barnard Y1 - 1996/08/01 UR - http://molpharm.aspetjournals.org/content/50/2/258.abstract N2 - A partial cDNA was isolated by hybridization screening of an embryonic chick brain library for P2Y purinoceptors. After extension to full length, it revealed an open reading frame that encoded a protein, P2Y3, of 328 amino acids that is nearest in sequence identity to the G protein-coupled P2 purinoceptors obtained by DNA cloning. Expression of P2Y3 in cRNA-injected Xenopus oocytes confirmed that this cDNA encodes a member of the metabotropic purinoceptor family, with a novel order for the relative activities of nucleotides. At 100 microM concentrations, ADP gave the highest activity, and UTP and UDP were also strongly active. When expressed in the human T cell line Jurkat, P2Y3 mediated transient increases in intracellular Ca2+ in response to various nucleotides. Again, an unusual agonist rank order was revealed, with uridine nucleotides being more potent than adenosine nucleotides and UDP being the most potent agonist tested (half-maximal concentration, 0.13 microM) and 10-fold more potent than UTP. 2-Methylthlo-ATP was of relatively low activity in both systems. The receptor transcript is expressed in brain, spinal cord, kidney, and lung and is highly abundant in the spleen but not in other peripheral tissues that we tested. The results indicated that P2Y3 is a previously unknown P2 purinoceptor subtype with a preference for nucleoside diphosphates. ER -